Open Access
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +15 more
Reads0
Chats0
TLDR
The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued development and standardization of methodologies for biomarkers and has provided an increased depth and breadth of data available to qualified researchers.About:
The article was published on 2017-04-01 and is currently open access. It has received 169 citations till now. The article focuses on the topics: Alzheimer's Disease Neuroimaging Initiative & Biomarker (medicine).read more
Citations
More filters
Journal ArticleDOI
Automated classification of Alzheimer's disease and mild cognitive impairment using a single MRI and deep neural networks
Silvia Basaia,Federica Agosta,Luca Wagner,Elisa Canu,Giuseppe Magnani,Roberto Santangelo,Massimo Filippi +6 more
TL;DR: A deep learning algorithm is built and validated predicting the individual diagnosis of Alzheimer's disease and mild cognitive impairment who will convert to AD (c-MCI) based on a single cross-sectional brain structural MRI scan, demonstrating that it is exploitable by not-trained operators and likely to be generalizable to unseen patient data.
Journal ArticleDOI
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
Dallas P. Veitch,Michael W. Weiner,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski +14 more
TL;DR: Select topics that provide insights into AD progression are discussed and how this knowledge may improve clinical trials are outlined.
Journal ArticleDOI
Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer’s Disease using structural MR and FDG-PET images
TL;DR: This paper proposes a novel deep-learning-based framework to discriminate individuals with AD utilizing a multimodal and multiscale deep neural network and delivers 82.4% accuracy and 94.23% sensitivity in classifying individuals with clinical diagnosis of probable AD.
Journal ArticleDOI
Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers.
Kwangsik Nho,Alexandra Kueider-Paisley,Siamak MahmoudianDehkordi,Matthias Arnold,Shannon L. Risacher,Gregory Louie,Colette Blach,Rebecca Baillie,Xianlin Han,Gabi Kastenmüller,Wei Jia,Guoxiang Xie,Shahzad Ahmad,Thomas Hankemeier,Cornelia M. van Duijn,John Q. Trojanowski,Leslie M. Shaw,Michael W. Weiner,P. Murali Doraiswamy,Andrew J. Saykin,Rima Kaddurah-Daouk +20 more
TL;DR: In this paper, the association of BAs with the "A/T/N" (amyloid, tau, and neurodegeneration) biomarkers for AD: cerebrospinal fluid (CSF), atrophy (magnetic resonance imaging), and brain glucose metabolism (FDG PET).
Journal ArticleDOI
Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology
Marc Suárez-Calvet,Marc Suárez-Calvet,Estrella Morenas-Rodríguez,Estrella Morenas-Rodríguez,Gernot Kleinberger,Kai Schlepckow,Miguel Ángel Araque Caballero,Nicolai Franzmeier,Anja Capell,Katrin Fellerer,Brigitte Nuscher,Erden Eren,Erden Eren,Johannes Levin,Johannes Levin,Yuetiva Deming,Laura Piccio,Celeste M. Karch,Carlos Cruchaga,Leslie M. Shaw,John Q. Trojanowski,Michael W. Weiner,Michael Ewers,Christian Haass,Christian Haass +24 more
TL;DR: CSF sTREM2 increased in early symptomatic stages of late-onset AD but, unexpectedly, was observed decreased at the earliest asymptomatic phase when only abnormal Aβ pathology but no tau pathology or neurodegeneration, is present.
References
More filters
Journal ArticleDOI
Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.
Anna Caroli,Annapaola Prestia,Sara Wade,Kewei Chen,Napatkamon Ayutyanont,Susan M. Landau,Cindee Madison,Cathleen Haense,Karl Herholz,Eric M. Reiman,William J. Jagust,Giovanni B. Frisoni +11 more
TL;DR: For all biomarkers and both MCI groups, power increased with increasing follow-up time, irrespective of biomarker assessment frequency, and imaging biomarkers of neurodegeneration showed highest performance.
Journal ArticleDOI
Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB binding
Andreas Lazaris,Kristy S. Hwang,Kristy S. Hwang,Naira Goukasian,Leslie Ramirez,Jennifer Eastman,Anna E. Blanken,Edmond Teng,Edmond Teng,Karen H. Gylys,Greg M. Cole,Greg M. Cole,Andrew J. Saykin,Leslie M. Shaw,John Q. Trojanowski,William J. Jagust,Michael W. Weiner,Liana G. Apostolova,Liana G. Apostolova +18 more
TL;DR: The data show that BIN1 rs744373, CD2AP rs9349407, and CR1 rs3818361 genotypes modulate the association between apoE protein plasma levels and brain amyloidosis, implying a potential epigenetic/downstream interaction.
Journal ArticleDOI
Altered regional brain volumes in elderly carriers of a risk variant for drug abuse in the dopamine D2 receptor gene (DRD2)
TL;DR: In both cohorts, the minor allele—previously linked with increased risk for addiction—was associated with larger volumes in various brain regions implicated in reward processing, suggesting that neuroanatomical phenotypes associated with familial vulnerability for drug dependence may be partially mediated by DRD2 genotype.
Journal ArticleDOI
Multiple kernel learning with random effects for predicting longitudinal outcomes and data integration.
TL;DR: A novel statistical learning method for longitudinal data is developed by introducing subject‐specific short‐term and long‐term latent effects through a designed kernel to account for within‐subject correlation of longitudinal measurements and allows easy integration of various heterogeneous data sources.
Journal ArticleDOI
A cognitive psychometric model for the psychodiagnostic assessment of memory-related deficits.
TL;DR: A Hidden Markov model of free recall is developed to measure latent cognitive processes used during the free-recall task and suggests that impaired patients appear to have no deficit in immediate recall of encoded words in long-term memory or for very short time intervals in STM.
Related Papers (5)
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Jesse M. Cedarbaum,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Johan Luthman,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Li Shen,Adam J. Schwarz,Arthur W. Toga,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +19 more
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.
Dallas P. Veitch,Michael W. Weiner,Paul S. Aisen,Laurel A. Beckett,Charles DeCarli,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Susan M. Landau,John C. Morris,Ozioma C. Okonkwo,Richard J. Perrin,Ronald C. Petersen,Monica Rivera-Mindt,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,Duygu Tosun,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +20 more